Clinical trials: Neoplasms, Metastatic
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.
- Trial name
- NCT03252808
- Testing
- TBI-1401(HF10), Gemcitabine, Nab-paclitaxel
- Where
- 8 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Takara Bio Inc.
Colorectal Cancer
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00066274
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- 17 sites in France
- Sponsor
- UNICANCER
Metastasis, Solid Tumor
Study of PAT in Patients With Solid Tumor Cancers
This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of…
- Trial name
- NCT05338658
- Testing
- Peptide Alarm Therapy (PAT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC).
- Trial name
- ENTHUSE M0 (NCT00626548)
- Testing
- ZD4054, Palcebo
- Where
- 322 sites in United States, Argentina and 37 more
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Stage IV Melanoma, Recurrent Melanoma
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00019448
- Testing
- gp100 antigen, interleukin-2
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
mCRPC
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
This trial is designed to evaluate the safety and efficacy of anti-IGF-1R mAb in combination with anti-PD-1 mAb in patients with mCRPC.
- Trial name
- NCT06866548
- Testing
- anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Shanghai Changzheng Hospital
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in…
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
- Trial name
- NCT00748215
- Testing
- calcium aluminosilicate anti-diarrheal
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Prostate Cancer, Therapy, Directly Observed
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy…
- Trial name
- NCT06350825
- Testing
- Cytoreductive prostatectomy or brachytherapy, ADT+second-generation antiandrogens ± chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-Squamous Non-Small Cell Lung Cancer
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients will be investigated in this clinical trial.
- Trial name
- NCT03802240
- Testing
- Sintilimab, IBI305, Pemetrexed
- Where
- China
- Volunteers
- 492 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Lung Cancer
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
RATIONALE: Vaccines made from a person's tumor cells may help the body build an effective immune response to kill non-small cell lung cancer cells.
- Trial name
- NCT00503568
- Testing
- Ad100-gp96Ig-HLA A1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Miami
Non-small Cell Lung Cancer
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: Cohort I: Patients previously treated…
- Trial name
- NCT00359450
- Testing
- BMS-275183 (oral taxane)
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer
This trial is to compare the efficacy and safety of modified FOLFOX6 [mFOLFOX6, a specific chemotherapy regimen of Oxaliplatin ,5-Fluorouracil and Leucovorin] chemotherapy plus Antigen Pulsed Dendritic Cells (APDC，a kind of…
- Trial name
- NCT02503150
- Testing
- APDC + Chemotherapy, Chemotherapy
- Volunteers
- 480 people
- Sponsor
- Second Military Medical University
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body.
- Conditions
- Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
- Trial name
- NCT01582191
- Testing
- Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Osteosarcoma, Relapsed Osteosarcoma
Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma
This is a trial for patients affected by metastatic or relapsed osteosarcoma which progressed after first or further line treatments.
- Trial name
- SERIO (NCT01804374)
- Testing
- Sorafenib, Everolimus
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Italian Sarcoma Group
Colon Cancer, MTHFR Gene Mutation
C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine Effectiveness in Metastatic Colon Cancer
Fluoropyrimidines are the backbone of chemotherapy regimes used to treat metastatic colorectal cancer (CRC). These drugs act in different pathways of folate metabolism altering DNA synthesis mainly by inhibition of the tymidylate…
- Conditions
- Colon Cancer, MTHFR Gene Mutation, Chemotherapeutic Toxicity, Chemotherapy Effect
- Trial name
- NCT03852290
- Where
- Costa Rica
- Volunteers
- 65 people
- Sponsor
- Universidad de Costa Rica
Metastatic, Uveal Melanoma
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Selumetinib therapy in patients with metastatic uveal melanoma.
- Trial name
- SUMIT (NCT01974752)
- Testing
- 75mg selumetinib, Dacarbazine
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
The study medication (BAY 2315497 Injection) is a thorium-227 labeled immuno-conjugate, specific for the prostate-specific membrane antigen (PSMA), which will be evaluated in patients with metastatic castration resistant prostate…
- Trial name
- NCT03724747
- Testing
- BAY2315497 Injection, Darolutamide(BAY1841788)
- Where
- 5 sites in United States, Finland and 1 more
- Volunteers
- 63 people
- Sponsor
- Bayer
Melanoma (Skin) Stage IV, Melanoma (Skin Cancer)
Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.
Previous research has shown that a higher fiber intake may have a beneficial effect on the intestinal health and improve the effectiveness of immunotherapy, but this is not certain.
- Conditions
- Melanoma (Skin) Stage IV, Melanoma (Skin Cancer), Melanoma Metastatic, Melanoma Advanced
- Trial name
- FIGURE-IM (NCT07686835)
- Testing
- Dried chicory roots
- Where
- 2 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Radboud University Medical Center
Locally Advanced Metastatic BRAF Mutant Melanoma
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
To evaluate the safety, tolerability and efficacy of LEE011 and LGX818 when administered orally to patients with BRAF mutant melanoma.
- Trial name
- NCT01777776
- Testing
- LEE011, LGX818
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 28 people
- Sponsor
- Array BioPharma
Non-small Cell Lung Cancer
Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
The primary objective of this study is to determine the overall response rate (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally…
- Trial name
- NCT00687817
- Testing
- bavituximab plus paclitaxel and carboplatin
- Where
- 9 sites in India
- Volunteers
- 49 people
- Sponsor
- Peregrine Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.